ReviewExperientia supplementum (2012)2026
Exploring the Role of Long Noncoding RNAs (lncRNAs) as Biomarkers in Cancers.
Review in Experientia supplementum (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The whole human genome sequence analysis has identified a large proportion of transcripts that lack protein-encoding function known as noncoding RNAs (ncRNAs). Long ncRNAs (lncRNAs) are transcripts consisting of more than 200 nucleotides. LncRNAs are identified as key regulators for diverse biological processes, including gene expressions, epigenetic modulations, transcriptional and translational regulation. LncRNAs-based mechanisms control gene activation, and cellular processes, while the dysregulated lncRNAs are associated with various disorders, including cancer. Moreover, lncRNAs have potential in diagnosis and prognosis of cancer. Several lncRNAs contribute to cancer development, metastatic cascade, and their molecular regulations in cancer development. The aberrant expression of lncRNAs regulates tumorigenesis, proliferation, metastasis, cancer stage, tumor size, and overall survival rates. Several lncRNAs are highly expressed or downregulated in several human tumors, behaving as oncogenes or tumor suppressors, respectively. The unique expression level of oncogenic lncRNAs provides a possibility to utilize them as a promising predictive biomarker of cancer.
Indexed as
Identifiers
41479114What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.